|
Incyte hopes its success with inhibitors is uninhibited. The biotechnology company is focused on discovering and developing drugs that inhibit specific enzymes associated with cancer, diabetes, HIV, and inflammatory diseases. The company's lede program is its JAK kinase inhibitor program, which covers treatments for inflammatory diseases and cancers, including rheumatoid arthritis, myelofibrosis, psoriasis, multiple myeloma, and prostate cancer. Incyte has several other products in clinical trial stages, including a CCR5 antagonist designed to prevent the entry of HIV into target cells.
|
| | | Contact Information | |
Address: |
Experimental Station, Route 141 & Henry Clay Road, Bldg. E336
Wilmington, DE 19880
| | Phone: | 302-498-6700 | | Fax: | 302-425-2750 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 3.90 M | | Revenue Growth (1 yr): | (-88.60%) | | Employees (2008): | 212 | | Employee Growth (1 yr): | 8.20% |
|
|
Key People
| | • |
Chairman:
Richard U. (Dick) De Schutter
| | • |
President, CEO and Director:
Paul A. Friedman
| | • |
EVP and CFO:
David C. Hastings
|
|
|
